Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P07614)

Inclusion Criteria: * Documented chronic hepatitis C (CHC) genotype 1 infection * Treatment naïve or failed previous interferon/ribavirin therapy (≥12 uninterrupted weeks) * Weigh between 10 kg to 90 kg inclusive at screening and baseline (Day -1). * Body Mass Index (BMI) from the 5th to the 95th percentile for the participant's age and gender, inclusive, per tables from the Center for Disease Control and Prevention, USA * Use of acceptable methods of contraception for at least 3 months prior to baseline and continue on study Exclusion Criteria: * Co-infection with the human immunodeficiency virus (HIV) or hepatitis B virus (HBsAg positive). * Treatment with ribavirin within 90 days, or any interferon-alfa within 30 days * Discontinued from interferon treatment due to adverse events * Currently receiving antiviral/immunomodulating therapy for hepatitis C * Prior treatment with an HCV protease inhibitor * Prior treatment with any known hepatotoxic agent (including herbal remedies) * Use of investigational drugs within 30 days of enrollment into study * Evidence of de-compensated liver disease including, but not limited to, a history or presence of clinical ascites, bleeding varices, or hepatic encephalopathy. * Substance abuse (including but not limited to alcohol abuse, illicit drugs, inhalational drugs, marijuana use, etc) any time prior to entry into the study * Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of any drug. * Pregnant or breastfeeding female * Meeting any of the laboratory exclusion criteria